Literature DB >> 30468644

Fibroblast activation protein in liver fibrosis.

Angelina J Lay1, Hui Emma Zhang1, Geoffrey William McCaughan1, Mark Douglas Gorrell2.   

Abstract

Fibroblast activation protein (FAP) belongs to the dipeptidyl peptidase IV (DPP4; CD26) gene family. Other related genes in this family of enzyme include DPP4, 8 and 9. The FAP serine protease has the rare property of both dipeptidyl peptidase and endopeptidase activities capable of cleaving the post-proline bond at two or more residues from the N-terminus. FAP is involved in a variety of biological processes but its expression in healthy tissues is low. In contrast, FAP is significantly elevated in pathological conditions such as at sites of tissue remodelling and repair. Its differential pattern of expression in diseases supports the emerging concept for FAP as a potential disease biomarker as well as a useful therapeutic target for drug intervention. This review summarizes the current knowledge of FAP, particularly its diagnostic and pathological significance in liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30468644     DOI: 10.2741/4706

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  10 in total

1.  Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP).

Authors:  An De Decker; Gwendolyn Vliegen; Dries Van Rompaey; Anke Peeraer; An Bracke; Line Verckist; Koen Jansen; Ruth Geiss-Friedlander; Koen Augustyns; Hans De Winter; Ingrid De Meester; Anne-Marie Lambeir; Pieter Van der Veken
Journal:  ACS Med Chem Lett       Date:  2019-07-09       Impact factor: 4.345

Review 2.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

3.  AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients.

Authors:  Allegra Kaufman; Lubna Abuqayyas; William S Denney; Erik J Tillman; Tim Rolph
Journal:  Cell Rep Med       Date:  2020-07-21

4.  Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2).

Authors:  Gwendolyn Vliegen; Kaat Kehoe; An Bracke; Emilie De Hert; Robert Verkerk; Erik Fransen; Bart 's Jongers; Esther Peters; Anne-Marie Lambeir; Samir Kumar-Singh; Peter Pickkers; Philippe G Jorens; Ingrid De Meester
Journal:  PLoS One       Date:  2020-04-21       Impact factor: 3.240

Review 5.  FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.

Authors:  Erik J Tillman; Tim Rolph
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-14       Impact factor: 5.555

6.  Fibroblast Activation Protein Specific Optical Imaging in Non-Small Cell Lung Cancer.

Authors:  Layla Mathieson; Richard A O'Connor; Hazel Stewart; Paige Shaw; Kevin Dhaliwal; Gareth O S Williams; Alicia Megia-Fernandez; Ahsan R Akram
Journal:  Front Oncol       Date:  2022-03-10       Impact factor: 6.244

7.  Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis.

Authors:  Jaiwoo Lee; Junho Byun; Gayong Shim; Yu-Kyoung Oh
Journal:  Nat Commun       Date:  2022-03-21       Impact factor: 14.919

8.  Evolving Up-regulation of Biliary Fibrosis-Related Extracellular Matrix Molecules After Successful Portoenterostomy.

Authors:  Antti Kyrönlahti; Nimish Godbole; Oyediran Akinrinade; Tea Soini; Iiris Nyholm; Noora Andersson; Maria Hukkinen; Jouko Lohi; David B Wilson; Marjut Pihlajoki; Mikko P Pakarinen; Markku Heikinheimo
Journal:  Hepatol Commun       Date:  2021-02-09

9.  Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients.

Authors:  Qun-Yan Yao; Ya-Dong Feng; Pei Han; Feng Yang; Guang-Qi Song
Journal:  World J Gastroenterol       Date:  2020-07-21       Impact factor: 5.742

Review 10.  The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence.

Authors:  Tianli Zhang; Xiang Tong; Shijie Zhang; Dongguang Wang; Lian Wang; Qian Wang; Hong Fan
Journal:  Front Pharmacol       Date:  2021-12-09       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.